These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 16773629

  • 1. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.
    Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, Bochner BH.
    Cancer; 2006 Aug 01; 107(3):506-13. PubMed ID: 16773629
    [Abstract] [Full Text] [Related]

  • 2. Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer.
    Tsao CK, Moshier E, Seng SM, Godbold J, Grossman S, Winston J, Oh WK, Galsky MD.
    Clin Genitourin Cancer; 2012 Mar 01; 10(1):15-20. PubMed ID: 22130294
    [Abstract] [Full Text] [Related]

  • 3. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer.
    Raj GV, Iasonos A, Herr H, Donat SM.
    J Clin Oncol; 2006 Jul 01; 24(19):3095-100. PubMed ID: 16809735
    [Abstract] [Full Text] [Related]

  • 4. [Impact of different methods of estimating renal function on determining eligibility for cisplatin (CDDP)-based chemotherapy in patients with invasive urothelial carcinoma].
    Goto T, Yoshimura K, Matsui Y, Shimizu Y, Inoue T, Okubo K, Kamba T, Nishiyama H, Ogawa O.
    Hinyokika Kiyo; 2011 Dec 01; 57(12):671-6. PubMed ID: 22240299
    [Abstract] [Full Text] [Related]

  • 5. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
    Muramaki M, Miyake H, Kurahashi T, Takenaka A, Inoue TA, Fujisawa M.
    Int J Urol; 2008 Apr 01; 15(4):314-8. PubMed ID: 18380818
    [Abstract] [Full Text] [Related]

  • 6. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients.
    Thompson RH, Boorjian SA, Kim SP, Cheville JC, Thapa P, Tarrel R, Dronca R, Costello B, Frank I.
    BJU Int; 2014 May 01; 113(5b):E17-21. PubMed ID: 24006893
    [Abstract] [Full Text] [Related]

  • 7. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN, Pansadoro V, Calabrò F, Schnetzer S, Giannarelli D, Emiliozzi P, De Paula F, Scarpone P, De Carli P, Pizzo M, Platania A, Amini M.
    Cancer; 2003 Apr 01; 97(7):1644-52. PubMed ID: 12655521
    [Abstract] [Full Text] [Related]

  • 8. Preoperative hydronephrosis: independent predictor for changes in renal function following nephroureterectomy.
    Hoshino K, Kikuchi E, Tanaka N, Akita H, Ito Y, Miyajima A, Jinzaki M, Oya M.
    Jpn J Clin Oncol; 2012 Mar 01; 42(3):202-7. PubMed ID: 22246718
    [Abstract] [Full Text] [Related]

  • 9. Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy.
    Canter D, Viterbo R, Kutikov A, Wong YN, Plimack E, Zhu F, Oblaczynski M, Berberian R, Chen DY, Greenberg RE, Uzzo RG, Boorjian SA.
    Urology; 2011 Jan 01; 77(1):160-5. PubMed ID: 20709369
    [Abstract] [Full Text] [Related]

  • 10. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
    Ennis RD, Petrylak DP, Singh P, Bagiella E, O'Toole KM, Benson MC, Olsson CA.
    J Urol; 2000 May 01; 163(5):1413-8. PubMed ID: 10751847
    [Abstract] [Full Text] [Related]

  • 11. Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function.
    Koshkin VS, Barata PC, Rybicki LA, Zahoor H, Almassi N, Redden AM, Fergany AF, Kaouk J, Haber GP, Stephenson AJ, Ornstein MC, Gilligan T, Garcia JA, Rini BI, Grivas P.
    Clin Genitourin Cancer; 2018 Aug 01; 16(4):e879-e892. PubMed ID: 29576445
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of adjuvant chemotherapy in transitional cell carcinoma of the urinary bladder with lymph node involvement and/or lymphovascular invasion treated by radical cystectomy.
    Park J, Park S, Song C, Doo C, Cho YM, Ahn H, Kim CS.
    Urology; 2007 Aug 01; 70(2):257-62. PubMed ID: 17826485
    [Abstract] [Full Text] [Related]

  • 13. Adjuvant chemotherapy in lymph node positive bladder cancer.
    Gofrit ON, Stadler WM, Zorn KC, Lin S, Silvestre J, Shalhav AL, Zagaja GP, Steinberg GD.
    Urol Oncol; 2009 Aug 01; 27(2):160-4. PubMed ID: 18440835
    [Abstract] [Full Text] [Related]

  • 14. Combination chemotherapy of ifosfamide, 5-fluorouracil, etoposide and cisplatin as perioperative treatment in lymph node positive bladder carcinoma patients treated by radical cystectomy.
    Komai Y, Fujii Y, Okubo Y, Yamamoto S, Kawakami S, Yonese J, Fukui I.
    Int J Urol; 2008 Oct 01; 15(11):971-5. PubMed ID: 18775029
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K, Higuchi A, Maruyama S, Minayoshi K, Fujii A, Itoh N, Hasunuma Y, Tanaka H, Izumi T.
    Jpn J Clin Oncol; 1993 Oct 01; 23(5):291-8. PubMed ID: 7693990
    [Abstract] [Full Text] [Related]

  • 16. A comparison of measured creatinine clearance versus calculated glomerular filtration rate for assessment of renal function before autologous and allogeneic BMT.
    Hahn T, Yao S, Dunford LM, Thomas J, Lohr J, Arora P, Battiwalla M, Smiley SL, McCarthy PL.
    Biol Blood Marrow Transplant; 2009 May 01; 15(5):574-9. PubMed ID: 19361749
    [Abstract] [Full Text] [Related]

  • 17. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
    Kuroda M, Kotake T.
    Gan To Kagaku Ryoho; 1994 Oct 01; 21 Suppl 3():362-9. PubMed ID: 7986116
    [Abstract] [Full Text] [Related]

  • 18. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
    Stöckle M, Meyenburg W, Wellek S, Voges GE, Rossmann M, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R.
    J Urol; 1995 Jan 01; 153(1):47-52. PubMed ID: 7966789
    [Abstract] [Full Text] [Related]

  • 19. Radical cystectomy in the elderly: Comparison of survival between younger and older patients.
    Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, Skinner DG.
    Cancer; 2005 Feb 01; 103(3):546-52. PubMed ID: 15630702
    [Abstract] [Full Text] [Related]

  • 20. Timing cystectomy and perioperative chemotherapy in the treatment of muscle invasive bladder cancer.
    Izawa JI, Chin JL, Winquist E.
    Can J Urol; 2006 Jun 01; 13 Suppl 3():48-53. PubMed ID: 16818012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.